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Background: Magnetic resonance-guided focused ultrasound (MRgFUS) is a relatively new minimally invasive
treatment, approved by the US Food and Drug Administration in 2004 for treatments of symptomatic uterine
leiomyomas (fibroids). The purpose of this work is to present retrospective cohort analysis of women that
underwent commercial MRgFUS treatment between 2005 and 2009 at a single center, to identify baseline patient
characteristics that predict successful MRgFUS fibroid treatment. Identifying these clinical predictors of MRgFUS
would be helpful to clinicians choosing the optimal patient for this treatment modality.
Methods: One hundred thirty women with symptomatic uterine leiomyomas who underwent MRgFUS were
followed up with a mean length of follow up of 17.4 ± 10.3 months. The main outcome measure of the follow-up
was to identify patients who required additional fibroid treatment due to continued fibroid symptoms. Additionally,
patient medical history and radiological findings obtained prior to MRgFUS were reviewed, and statistical analysis
was performed to identify factors associated with reduced risk of having additional fibroid treatment.
Results: Twenty-nine patients (22.3%) underwent additional fibroid treatment due to continued or recurrent fibroid
symptoms during the follow up. Cumulative incidence of additional fibroid treatment was 9.7%, 29.3%, and 44.7%
at 1, 2, and 3 years following MRgFUS, respectively. In multivariable Cox proportional hazard regression analyses,
older age (hazard ratio (HR) 0.54 per 5-year increase in age, 95% confidence interval 0.39 to 0.76, p < 0.001), greater
number of fibroids (HR 0.19 for more than three vs. one fibroid, 95% CI 0.05 to 0.67, p = 0.033), and greater fibroid
volume (HR 0.70 per doubling in volume, 95% CI 0.51 to 0.96, p = 0.025) were significantly associated with less risk
of having additional fibroid treatment.
Conclusions: Older age at treatment and having multiple fibroids with larger volume are associated with a lower
risk of additional intervention following MRgFUS treatment for uterine fibroids.
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Uterine leiomyomas (fibroids or myoma) are benign
clonal tumors that arise from the smooth muscle cells of
the myometrium [1]. They are the most common gyne-
cologic neoplasm in women of reproductive age and are
clinically noted in up to 25% of all women [2,3]. Studies
using both ultrasound and pathologic examination of
surgical uterine specimens suggest an overall prevalence
of uterine fibroids of over 70% [4-6].
Fibroids can cause a variety of symptoms [7], which
can generally be classified into three distinct categories:
increased heavy menstrual bleeding, pelvic pressure and
pain, termed bulk-related symptoms, and reproductive
dysfunction [1].
Historically, hysterectomy has been employed as the
major treatment option for uterine fibroids. However,
there is an increasing array of less invasive alternatives to
hysterectomy for the control of uterine fibroids [3,7]. Mag-
netic resonance-guided focused ultrasound (MRgFUS) is a
relatively new treatment option, which was approved by
the US Food and Drug Administration (FDA) in 2004
specifically for treatments of uterine fibroids. This nonin-
vasive thermoablative technique uses phased array ultra-
sound transducer to focus a beam of ultrasound energy on
a target site, causing localized coagulative necrosis. The
transducer is integrated with a magnetic resonance
imaging (MRI) scanner. MRI is used for anatomical treat-
ment planning, ultrasound beam guidance and near real-
time thermal feedback, and ablation assessment upon
completion of treatment.
There is accumulating evidence on the efficacy and
safety of MRgFUS in the treatment of symptomatic uter-
ine leiomyomas [8]. However, little is known which
fibroid patients are best candidates for this treatment
modality. Recently published retrospective analysis of 81
patients [9] indicated that older women with fibroids
presenting as hypointense in T2-weighted MR images
are more likely to benefit from MRgFUS. In this work,
we present similar analysis based on 130 patients treated
between March 2005 and December 2009 at our institu-
tion. Description of this patient cohort, details of the
treatments, and their 12-month outcome were presented
elsewhere [10-12]. Our aim in this work is to determine
which patient characteristics available to the physician in
the screening process can predict successful MRgFUS
treatment (defined as lack of additional intervention due
to fibroid-related symptoms). The analysis is based on
pretreatment patient screening, which includes MRI
findings and review of patient medical history and pre-
senting symptoms.
Materials and methods
This retrospective cohort analysis was conducted at Mayo
Clinic, Rochester, Minnesota. Women with symptomaticuterine fibroids treated with MRgFUS between March
2005 and December 2009 were included in the study.
Patients who denied the use of their data for research pur-
poses were excluded. The study was approved by the
Mayo Clinic Institutional Review Board (IRB).
MRgFUS treatments
Treatments were performed using the ExAblate 2000
focused ultrasound device (InSightec, Haifa, Israel) inte-
grated with MRI scanner (Signa Excite, GE Healthcare,
Milwaukee, Wisconsin, USA). Details of the MRgFUS
treatments have been published elsewhere [10-12]. All pa-
tients underwent a pretreatment MRI with gadolinium
contrast. Patients were treated on an outpatient basis.
Intravenous conscious sedation, using combination of
midazolam hydrochloride and fentanyl citrate (typical dose
of 0.5 mg midazolam and 25 μg fentanyl), was used during
the course of the procedure to maintain patient comfort
and allow communication with the treating physician [13].
At the end of the procedure, MR images with gadolinium
contrast were acquired to assess the treatment and meas-
ure the non-perfused (i.e., ablated) volume (NPV), which
previous studies have shown to correlate with the volume
of coagulative necrosis caused by treatment [13].
Fibroid classification and volume measurements
Methods described previously by Gorny et al. [12] were
used in image analysis and fibroid volume measurements.
The measurements were performed in consensus between
two radiologists and a medical physicist experienced in
MRI and MRgFUS treatments (all with at least 7 years of
experience). Fibroids were categorized according to their
T2 signal intensity in the MRI screening: ‘dark with
minimal heterogeneity’ (signal intensity lower than that
of myometrium, less than 25% heterogeneous), ‘dark
with substantial heterogeneity’ (signal intensity lower than
that of myometrium, more than 25% heterogeneous),
‘isointense’ (signal intensity equal to that of myometrium),
and ‘bright’ (signal intensity greater than that of myome-
trium). The volumetric measurements were performed
using Vitrea® 2.2 (ver. 3.0, Vital Images, Inc., Minnetonka,
MN, USA) segmentation software. T2-weighted treat-
ment-planning images were used to measure fibroid vol-
umes. T1-weighted images, with gadolinium contrast,
acquired upon completion of the treatment, were used to
measure NPV defined as the sum of all non-perfused
(ablated) fibroid tissues. For each patient, the following
quantities were recorded: the cumulative volume of all
fibroids within the uterus (total fibroid load), the volume
of the dominant (largest) fibroid, and the ratio of NPV to
the total fibroid load (NPV ratio).
Following the focused ultrasound procedure, patients
were interviewed by phone after 3 and 6 months and
yearly thereafter to assess symptom relief and additional
Gorny et al. Journal of Therapeutic Ultrasound 2013, 1:15 Page 3 of 9
http://www.jtultrasound.com/content/1/1/15procedures undertaken for relief of fibroid-related symp-
toms. From the beginning of 2007, patients were
additionally asked to complete the Uterine Fibroid
Symptom Quality-of-Life [14] questionnaire at baseline,
and 6 and 12 months of follow up.Patient follow up
For each patient, an extensive review of ambulatory and
inpatient medical records at our institution was
conducted. Information regarding patient demographics,
disease history and symptoms, and NPV and NPV ratios
was abstracted. The primary outcome assessed was
whether or not the patient had an additional fibroid
procedure (e.g., hysterectomy, myomectomy, MRgFUS)
during the follow up. The treatment was considered suc-
cessful if the patient did not have an additional procedure
for fibroid-related symptoms during the follow-up period.
Additional procedures due to continued or recurrent
fibroid symptoms were limited to subsequent hysterec-
tomy, myomectomy, uterine artery embolization (UAE),
endometrial ablation, or retreatment with MRGFUS. Hor-
monal gonadotropin-releasing hormone (GnRH) agonist
therapy during the follow-up period (such as Lupron) was
not considered as an additional procedure.Statistical analysis
Time-to-event methodologies were used to evaluate hav-
ing additional treatment due to continued fibroid symp-
toms or recurrence of fibroid symptoms, taking into
account the varying duration of follow up. Duration of
the follow up was calculated from the time of the initial
MRgFUS procedure to the date of the subsequent add-
itional procedure for women failing the treatment. For
women undergoing an additional procedure for reasons
other than symptom recurrence, their follow up was
censored at the date of that additional procedure. For
patients who did not undergo additional procedures dur-
ing the follow-up period, the follow up was censored at
the date of last contact or at the onset of menopause.
The Kaplan-Meier method was used to estimate the cu-
mulative incidence of additional procedures [15]. Cox
proportional hazard models were fit to evaluate factors
associated with the need for additional procedure [16].
Univariate models were fit to identify variables with a
p value of less than 0.40 as candidate predictors of hav-
ing an additional treatment. The candidate predictors
were then considered in a multivariate Cox proportional
hazard analysis, in which a parsimonious model was iden-
tified using stepwise and backward variable selection
methods. Associations were summarized using the hazard
ratio (HR) and corresponding 95% confidence intervals
(CI). All calculated p values were two-sided, and p values
less than 0.05 were considered statistically significant.Results
Between March 2005 and December 2009, 144 women
completed MRgFUS treatment at our institution. Four-
teen patients denied the use of their data for research
purposes prior to treatment; therefore, our study cohort
consists of 130 women. Descriptive statistics of the treat-
ments and their immediate outcomes are provided else-
where [10-12].
Characteristics and history of the cohort are presented
in Tables 1 and 2. The mean length of follow up in our
cohort was 17.4 ± 10.3 months. Over this period, 29 pa-
tients received additional treatment due to continued or
recurrent fibroid symptoms. The cumulative incidences
of additional fibroid treatment were 9.7% (95% CI 4.1 to
15.0%; number still at risk 94), 29.3% (95% CI 18.0 to
39.1%; number still at risk 35), and 44.7% (95% CI 26.4
to 58.6%; number still at risk 12), 1, 2, and 3 years fol-
lowing MRgFUS treatment, respectively. ‘Number still at
risk’ represents the number of patients with a duration
of follow up more than t, at t years following the initial
MRgFUS. The mean interval of additional treatment was
16.7 ± 10.1 months, the earliest occurring 6.2 months
following MRgFUS, and the latest at 49.6 months.
Among the patients who underwent additional treat-
ments, 19 had hysterectomy, 6 had myomectomy, 2 had
uterine artery embolization, 1 had endometrial ablation,
and 1 had retreatment with MRgFUS. Furthermore, there
were three patients who underwent additional treatment
for reasons other than fibroid-related symptoms: one pa-
tient underwent a hysterectomy because her gynecologist
was not able to successfully perform a Papanicolaou test,
one woman underwent a myomectomy during surgery for
a pancreatic tumor, and one patient underwent myomec-
tomy because of infertility issues.
Cell counts may not sum to or exceed 130 because of
missing data or multiple conditions that apply; aTerm
‘Transmural’ refers to a fibroid that is predominately
intramural but occupies full thickness of the myome-
trium, extending from the endometrium to the serosa.
Table 3 summarizes patient and fibroid characteristics
that were evaluated using univariate Cox models for an
association with subsequent treatment for fibroids. As il-
lustrated in Figure 1, women who were initially treated
at an older age were significantly less likely to have sub-
sequent treatment; the estimated hazard or risk ratio
was 0.63 per 5-year increase in age (p = 0.003), implying
that an increase in age of 5 years is associated with 37%
less likelihood of having an additional procedure.
Women with a history of pelvic or uterine surgery were
2.3 times more likely to have subsequent treatment for
fibroids compared to women without a prior surgery
(p = 0.042). In addition, (n = 7) women who previously
used GnRH agonist (e.g., Lupron) therapy were 3.9 times
more likely to have subsequent treatment for fibroids
Table 1 Characteristics of the cohort (n = 130)
Characteristic Mean ± SD
Patient
Age at treatment (years) 45.1 ± 5.5
BMI (kg/m2) (n = 95)
<25 52 (54.7)
25 to 29 26 (27.4)
≥30 17 (17.9)
Race (n = 88)
Caucasian 77 (87.5)
Other 11 (12.5)
Smoking history (n = 123)
No 82 (66.6)
Yes 41 (33.3)
Gravidity (n = 129)
Nulligravid 59 (45.7)
Multigravid 70 (54.3)
Parity (n = 129)
Nulliparous 70 (54.3)
Multiparous 59 (45.7)








Endometrial ablation 2 (1.5)
MRgFUS 8 (6.2)
Symptom
Age at first diagnosis (years) (n = 104) 41.5 ± 6.2
Duration of dominant symptom (months) (n = 98) 20.6 ± 15.7
Presenting symptoms (n = 124)
Bleeding + Bulk 39 (31.0)
Bleeding only 32 (25.4)
Bulk only 35 (27.8)
Pain (±Bleeding or Bulk) 20 (15.9)
Baseline symptom severity score (n = 66) 59.1 ± 18.0
Fibroid
Fibroid load (cm3) 350 ± 307
Volume dominant fibroid (cm3) 305 ± 292
Number of fibroids
1 50 (38.5)
2 or 3 39 (30.0)
>3 41 (31.5)
Table 1 Characteristics of the cohort (n = 130) (Continued)
Fibroid location




T2 signal intensity dark, minimal heterogeneity 71 (54.6)
Minimal heterogeneity
Minimal heterogeneity 71 (54.6)
Substantial heterogeneity 44 (33.8)
Isointense 6 (4.6)
Bright 9 (6.9)
Table 2 History of the cohort (n = 130)
History n (%)
Medical









Sexually transmitted disease 9 (6.9)
Thyroid disease 20 (15.4)
Medication
Analgesics 28 (21.5)
Antihypertensive medication 12 (9.2)
Iron suppletion 33 (25.4)
GnRH agonist 7 (5.4)
Oral contraceptives, psychofarmaca 27 (20.8)
18 (13.8)
Thyroid hormone 18 (13.8)
Surgical
Appendectomy 12 (9.2)
Caesarian section 5 (3.8)
Dilatation and curettage 18 (13.8)
Laparoscopy 10 (7.7)
Laparotomy 9 (6.9)
Pelvic floor reconstruction 1 (0.8)
Tubal ligation 16 (12.3)
Surgery for cervical dysplasia 15 (11.5)
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Table 3 Patient and fibroid characteristics evaluated
using univariate analysis
Characteristic HR (95% CI)a Univariate
Cox models
p value
Age at treatment (years) 0.63 (0.46 to 0.86) 0.003
BMI (kg/m2) 0.90 (0.64 to 1.28) 0.57
Ever pregnant (yes vs. no) 0.72 (0.34 to 1.52) 0.39
Ever live birth (yes vs. no) 0.80 (0.38 to 1.71) 0.57
Smoking history (yes vs. no) 0.45 (0.18 to 1.12) 0.09
Symptom severity score (SSS)b 1.18 (0.87 to 1.59) 0.29
Duration of dominant
symptom (months)
0.95 (0.79 to 1.15) 0.60
Pelvic pressure (yes vs. no) 0.42 (0.20 to 0.89) 0.023
Back pain (yes vs. no) 0.53 (0.13 to 2.26) 0.39
Presenting symptoms 0.94
Bleeding only Referent
Bulk only 0.78 (0.27 to 2.25)
Bleeding and bulk 0.77 (0.30 to 1.96)
Pain (with or without
bleeding or bulk)
0.76 (0.23 to 2.51)
Past medical history
Anemia (yes vs. no) 0.50 (0.22 to 1.13) 0.10
Hypertension (yes vs. no) 1.95 (0.46 to 8.36) 0.37
History of asthma (yes vs. no) c 0.10
History of migraines (yes vs. no) 2.00 (0.92 to 4.35) 0.08
History of pelvic or uterine
surgery (yes vs. no)
2.29 (1.03 to 5.08) 0.042
Thyroid disease (yes vs. no) 1.56 (0.63 to 3.84) 0.34
Prior GnRH agonist therapy 3.92 (1.33 to 11.51) 0.013
Prior usage of oral contraceptives
(yes vs. no)
2.02 (0.84 to 4.85) 0.11
Prior iron supplementation
(yes vs. no)
0.63 (0.26 to 1.56) 0.32
Prior thyroid hormone therapy
(yes vs. no)
1.56 (0.63 to 3.84) 0.34
Fibroid characteristic
Prior treatment (yes vs. no) 1.58 (0.71 to 3.51) 0.26
Fibroid type 0.52
Submucosal 1.36 (0.51 to 3.65)
Subserosal 0.4 (0.09 to 1.72)
Transmural 0.78 (0.18 to 3.35)
Intramural Referent
Number of fibroids 0.029
1 Referent
2 to 3 0.65 (0.28 to 1.52)
>3 0.19 (0.06 to 0.66)
Volume of largest fibroid (cm3) 0.80 (0.61 to 1.06) 0.11
Table 3 Patient and fibroid characteristics evaluated
using univariate analysis (Continued)
Total fibroid volume (cm3) 0.70 (0.52 to 0.95) 0.022
T2 signal intensity
“Dark with min. heterogeneity”
vs. all others
0.73 (0.35 to 153) 0.40
All dark vs. “isointense” and “bright” 0.85 (0.29 to 2.45) 0.76
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agonist (p = 0.013). The median NPV values were not
significantly between the two groups (115.7 (n = 7) vs.
126 (n = 123), Wilcoxon rank sum test p = 0.31).
Patient characteristics were evaluated for an associ-
ation with subsequent treatment (p values based on the
Wald test within the Cox model); aHR, hazard ratio esti-
mated from univariate Cox regression models. HR per
5-year increase in age, 5-unit increase in BMI, 10-unit
increase in SSS score, 6-month increase in the duration
of symptoms, doubling in volume of largest fibroid, and
doubling in total fibroid volume; b10-point Symptom
Severity Scale of the Uterine Fibroid Symptom Quality-
of-Life (UFSQOL) questionnaire; cUnable to estimate
the HR for a history of asthma since none of the patients
with a history of asthma have had subsequent fibroid
treatment.
Patients with either two to three or more than three
fibroids were less likely to have subsequent treatment
compared to those with a single fibroid (Figure 2,
p = 0.029). As illustrated in Figure 3, women with a
greater total fibroid volume were less likely to have sub-
sequent treatment; the estimated hazard ratio was 0.70
per a doubling in fibroid volume (p = 0.022).
The results of the multivariable analysis are summa-
rized in Table 4. In the multivariable Cox model, older
age (HR = 0.54 per 5-year increase in age, 95% CI 0.39 to
0.76, p < 0.001), greater number of fibroids (HR = 0.19
for more than three vs. one fibroid, 95% CI 0.05 to 0.67,
p = 0.033), and greater fibroid volume (HR = 0.70 per
doubling in volume, 95% CI 0.51 to 0.96, p = 0.025) were
significantly associated with less risk of having additional
fibroid treatment.
Discussion
MRgFUS is a minimally invasive procedure and unique
such that it is a noninvasive treatment which is adminis-
tered transabdominally. Appropriate patient selection is
essential to maximize the treatment's efficacy, and by
identifying factors that influence treatment outcome, the
profile of an ideal candidate for MRgFUS can be devel-
oped [17]. Knowledge of recurrence rates and prognostic
variables is useful to clinicians counseling patients and
choosing the optimal treatment.
Figure 1 Kaplan-Meier estimates of cumulative incidence of additional fibroid treatment by age subgroups.
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toms are typically expected to improve within several
months. For this reason, all the patients had the oppor-
tunity of at least 6 months of follow up as the last
MRgFUS treatment was in December 2009, and the fol-
low up was assessed through July 2010. However, nine
patients have less than 6 months of follow up either be-
cause they were lost to follow up (n = 8) or had a myo-
mectomy for non-fibroid-related issues (n = 1). These
women have all been retained in the analysis and were
appropriately censored in the time-to-event analyses.Figure 2 Kaplan-Meier estimates of cumulative incidence of additiona
two to three or more than three fibroids were less likely to have subsequeEvery uterus-sparing treatment modality for leiomyomas
has a substantial risk of clinical failure due to the possibil-
ity of leiomyoma recurrence. Several groups reported on
recurrence rates and additional treatments associated with
uterine-sparing fibroid therapies such as myomectomy
[18-20] and UAE [21-23]. Cumulative risk of recurrence
5 years following abdominal myomectomy was reported
as 62% (9% additional treatments, report based on 145
patients) [20]. For laparoscopic myomectomy, reported
cumulative recurrence risks were 31.7% in 3 years and
51.5% in 5 years (12% additional treatments, study basedl fibroid treatment by the number of fibroids. Patients with either
nt treatment compared to those with a single fibroid (p = 0.029).
Table 4 Results of multivariate analysis
Characteristic HR (95% CI)a P Value
Age at treatment (years) 0.54 (0.39 to 0.76) <0.001
Number of fibroids 0.033
1 Referent
2 to 3 0.89 (0.37 to 2.14)
>3 0.19 (0.05 to 0.67)
Total fibroid volume (cm3) 0.70 (0.51 to 0.96) 0.025
aHR, hazard ratio per 5-year increase in age and doubling in total fibroid
volume, respectively.
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up study of 200 patients after UAE, Spies et al. [23] found
rate of recurrence or symptom control failure of 25%
(19.7% additional treatments) 5 years after embolization.
In our cohort, cumulative rates of additional fibroid treat-
ment in 1, 2, and 3 years, were respectively 9.7%, 29.3%,
and 44.7%, which are within the upper range of data
reported for myomectomy and UAE. Our patient popula-
tion could arguably be at a higher than average risk of
needing additional intervention since a quarter of the
women had already had one fibroid intervention which
failed to control their symptoms. Additionally, this series
reports on the earliest non-study experience with a novel
technique with no predicate learning curve and known
suboptimal treatments in many cases.
In agreement with the recent published report on clin-
ical predictors of treatment success [9], we find that
MRgFUS treatment at a younger age is associated with
increased risk of needing additional treatment. One sim-
ple explanation for this finding is that the time duration to
the onset of menopause for younger women is longer leav-
ing them at a higher risk of fibroid recurrence or a clinical
treatment failure. It could also be argued that the severity
of the fibroid disease (measured by the severity of symp-
toms) is increased in women with an earlier disease onset,
which could lead to higher recurrence rates [23].
Higher risk of additional intervention was found in
women with single vs. multiple fibroids and in women
with a lower fibroid volume. There have been somewhat
conflicting reports of similar analyses on the predictors
of abdominal myomectomy and UAE. While our result
supports the findings of Stewart et al. [24], it is inFigure 3 Kaplan-Meier estimates of cumulative incidence of additionacontrast with those of Hanafi [20] who reported the cu-
mulative recurrence 5 years after abdominal myomec-
tomy to be significantly lower in patients with single
leiomyomata than in those with multiple leiomyomata.
Similarly, Spies et al. [23] also associated larger fibroid
volume with higher risk of further intervention. The size
and location of uterine fibroids are related to different
karotypic abnormalities representing differences in gene
expression [24-27]. Therefore, these conflicting results
could be associated with different biologic expressions of
the fibroid disease and varied response to treatments
and different patient populations. Future studies are ne-
cessary to correlate cytogenetic studies with clinical out-
comes. Lastly, our result may perhaps reflect some
difficulty of MRgFUS to adequately treat the entire vol-
ume of a single dominant fibroid vs. smaller fibroids.
Prior studies have shown that fibroids which are
hypointense on screening T2-weighted MRI respond op-
timally to MRgFUS with maximized non-perfused vol-
ume (NPV) and highest shrinkage following treatmentl fibroid treatment by total fibroid volume subgroups.
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long-term follow up [9]. In our cohort, data regarding
T2 signal intensity were analyzed from the perspective
of ‘dark with minimal heterogeneity’ vs. all others, and
‘all dark’ (regardless of the degree of their heterogeneity)
vs. all others. Regardless of the approach, no statistically
significant association between the fibroid T2 appear-
ance and either of these key outcomes was found (see
Table 3). One likely explanation for this is that a rela-
tively small population in ‘isointense’ and ‘bright’ fibroid
groups in our patient cohort (11.6% of all fibroids) in-
hibits in-depth statistical analysis.”
The role of MRgFUS is similar to the role of other
uterine-sparing procedures, which all have risks of recur-
rence and further interventions. The finding that younger
age at treatment is associated with increased risk of need-
ing further intervention may be viewed as disappointing
to younger women. However, in the light of the recently
reported high rate of ongoing and delivered pregnancies,
post-MRgFUS [29], this therapeutic modality should be
considered as a reasonable and safe treatment option to
those young women who wish to conceive.
It is reassuring that presenting symptomatology did
not influence treatment outcome. Moreover, concurrent
diagnoses such as adenomyosis or endometriosis were
not significant factors, but we lack statistical power to
make meaningful statistical conclusion since few of our
patients had these conditions at the time of treatment.
The limitations of the study include the retrospective
study design and significant prevalence of women of
Caucasian descent. Also, defining successful treatment
in terms of lack of additional interventions is somewhat
limited since it potentially excludes patients who had
either recurrence of symptoms, or insufficient symptom
relief but did not seek further medical treatment.
In conclusion, we find that older women, with several
fibroids and higher fibroid volume are more likely to
benefit from the MRgFUS treatment. Additionally, the
incidence of additional treatments post MRgFUS for
fibroid-related symptoms (during the follow up) is com-
parable with those published for other minimally inva-
sive uterine-sparing treatments (e.g., UAE).
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